Cerebrolysin is a peptide preparation derived from porcine brain tissue, studied in research for neurotrophic and neuroprotective signaling.
$10.47$14.95Eppix Flash Sale −30%CAD
⚡ Flash sale −30%Ends in 00:00:00Applied automatically at checkout
Mix & Match
1 vial — no vial discount yet.
Add 2 more vials for 5% off.
After that, 10% at 5 vials, 20% at 10 vials.
Purity VerifiedLab TestedSecure
Research Use Only
This product is intended strictly for laboratory research use within Canada. It is not approved by Health Canada for the diagnosis, treatment, cure, or prevention of any disease. Not for human or veterinary use.
By purchasing, you confirm the material will be used solely for lawful research purposes in accordance with applicable Canadian regulations.
Cerebrolysin is a peptide preparation derived from porcine brain tissue, studied in research for neurotrophic and neuroprotective signaling.
Experimental models examine its influence on neuronal survival and recovery pathways in neurological research frameworks.
Purity
Third-party tested for purity, ID, quantity.
Coming Soon
The certificate of analysis for the 30mg lot is being finalised and will be published here as soon as the lab returns it.
Compound Properties
Overview
Cerebrolysin is a standardized mixture of low-molecular-weight neuropeptides and amino acids characterized in research for neurotrophic activity resembling endogenous growth factors. Investigations have examined its effects on neuronal survival, plasticity, and recovery in stroke, traumatic-brain-injury, and neurodegeneration models.
Studies evaluate neuroprotective and neurorestorative endpoints under structured conditions.
History
Cerebrolysin was developed from research into brain-derived peptide preparations with neurotrophic activity.
A substantial body of clinical and preclinical literature has since examined its role in neurological recovery models.
Key Research Areas
Research into cerebrolysin focuses on neurotrophic and neuroprotective signaling. Frameworks evaluate neuronal survival, plasticity, and recovery endpoints across stroke, TBI, and neurodegeneration models under controlled conditions.
2 of the 4 areas below are addressed directly by a paper cited on this page.
Neurotrophic-factor signaling models
No paper cited on this page reports on neurotrophic or factor. This heading marks where Cerebrolysin is discussed in the category rather than a question the cited literature answers, and it is worth knowing which of these areas has work behind it and which does not.
Neuroprotection and recovery research
Addressed on this page by Brainin 2018. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.
Brainin, M. (2018) — Cerebrolysin: a multi-target drug for recovery after stroke
Stroke and TBI research frameworks
Addressed on this page by Brainin 2018. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.
Brainin, M. (2018) — Cerebrolysin: a multi-target drug for recovery after stroke
Neurodegeneration endpoint studies
No paper cited on this page reports on neurodegeneration or endpoint. This heading marks where Cerebrolysin is discussed in the category rather than a question the cited literature answers, and it is worth knowing which of these areas has work behind it and which does not.
The references section of this page cites 3 primary papers published between 2011 and 2023 — a thin record. Every citation is linked to its PubMed or DOI record so it can be read rather than taken on trust, and the summaries above describe what those papers report rather than what the compound is claimed to do.
Cerebrolysin is frequently listed as a peptide by suppliers in this market. It is not one. The structure published on this page is the compound's actual chemistry, and research on it should be read against its own class rather than against peptide literature.
Research compounds attract claims that outrun their evidence. Below are the ones most often encountered for Cerebrolysin, set against what the papers cited on this page actually report. Where the record is thin or contested, that is stated rather than smoothed over.
Also called
Cerebrolysin is also referred to as cere.
Human trial data exists
Cerebrolysin is commonly described online in connection with sharper focus, better memory and improved mood. In the research literature the same compound is filed under neurotrophic-factor signaling models, neuroprotection and recovery research and stroke and TBI research frameworks.
Of the 3 papers cited on this page, published between 2011 and 2023, 1 reports work in human participants — Jarosz 2023. Human data for a molecule is not the same as evidence for material supplied as a research compound: published trials use pharmaceutical-grade product under medical supervision at defined doses. What is established for the material sold here is its measured purity and content per lot.
Nothing above is a statement of what this material does. It is a summary of what has been published and what has not. Eppix Labs supplies research materials only and provides no dosing, administration or protocol guidance.
Every lot of Cerebrolysin is independently assayed before it is released, and the certificate for the lot shipped is published rather than summarised. Where a certificate for a current lot is not yet posted, the lot has not yet been released against it.
Researchers who buy Cerebrolysin in Canada through Eppix Labs receive a batch-labelled vial whose certificate is published against that lot code, so the material can be matched to its analysis rather than to a generic specification.
−20 °C long-term; stable at room temperature in transit
After reconstitution
2–8 °C
Light
Protect from UV and direct light
Freeze-thaw
Avoid repeated cycles
Vehicle
Solvent selection depends on the compound; consult the published literature
Format
Lyophilized powder
Cerebrolysin is supplied as lyophilized powder. It is not a peptide, and solvent behaviour follows from its own chemistry rather than from the aqueous-vehicle conventions that apply to peptide material — the published literature for this compound is the reference for solvent selection, not a general peptide protocol.
Dry storage below freezing and protection from light are the general controls. As with any lyophilized material, the powder frequently sits as a thin film at the base of the vial and is easy to mistake for an empty vial before inspection.
Vials may appear empty on arrival. Lyophilized material collects at the base of the vial and is often not visible until the vial is inspected under direct light.
1 × sealed glass vial in the strength selected (30mg / Single Vial, 60mg / Single Vial, 30mg / 5-Pack, 30mg / 10-Pack, 60mg / 5-Pack, 60mg / 10-Pack available), batch-labelled
Batch documentation for the lot shipped, once its certificate is published
Discreet outer packaging with no product names on the exterior
Canada Post Xpresspost, tracked, typically 1–2 business days from Canadian stock
Not included
Bacteriostatic water or any other reconstitution vehicle
Syringes, needles or filters
Dosing, administration or protocol guidance of any kind
Reconstitution materials are sourced separately. The reconstitution calculator on this site works out concentrations for a given volume, but it is an arithmetic tool for laboratory record-keeping and not a protocol.
No. Eppix Labs products are supplied exclusively for laboratory research. We do not provide dosing, administration, or usage guidance.
Each unit contains the labeled quantity of cerebrolysin. Independent third-party analysis verifies purity, identity, and net content per batch.
The unit contains only the research compound. Any laboratory materials required for reconstitution or experimental procedures must be sourced separately.
Duration depends entirely on research design, storage conditions, and laboratory protocol.
Brainin, M.(2018)
Cerebrolysin: a multi-target drug for recovery after stroke
Triple GIP / GLP-1 / Glucagon Agonist · 10, 20, 40 & 120 mg
Retatrutide is a synthetic peptide developed for controlled laboratory research involving multi-receptor signaling systems. It is structurally designed to interact with GLP-1, GIP, and glucagon receptor pathways within experimental environments.
Dual GIP / GLP-1 Agonist · 10, 30 & 65 mg
Tirzepatide is a synthetic peptide developed for controlled laboratory research involving dual incretin receptor signaling systems. It is structurally designed to interact with GLP-1 and GIP receptor pathways within experimental environments.
GLP-1 Receptor Agonist · 10 mg
Semaglutide is a synthetic analogue of glucagon-like peptide-1 (GLP-1), a naturally occurring incretin hormone involved in glucose-dependent signaling. It is developed for controlled laboratory investigation within regulated experimental environments.
Selective Amylin Agonist (LY3841136) · 10 mg
This product is supplied as eloralintide (LY3841136), a long-acting, selective amylin receptor agonist studied in research on metabolic and body-weight regulation.
Have questions about batch verification, documentation, or research specifications? Our team is available to assist with product and compliance inquiries.